After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 4:37PM CST
NOW: 63.58 (+0.14), WIT: 11.24 (-0.04), AG: 4.32 (-0.07), DGII: 8.11 (+0.18), BBEP: 7.65 (+0.70), NGD: 3.79 (-0.11), IAG: 2.21 (-0.12), VIIX: 46.87 (+2.10), PRTA: 18.50 (+0.88), CDE: 4.57 (+0.25)
Prothena mAb Fast Track'd for AL Amyloidosis
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 4:05PM CST
PRTA: 18.50 (+0.88)
Prothena Receives FDA Fast Track Designation for NEOD001, a Monoclonal Antibody for the Treatment of Patients With AL Amyloidosis
GlobeNewswire - Mon Dec 15, 3:10PM CST
-- First Investigational Immunotherapy for AL Amyloidosis to Receive FDA Fast Track Designation
PRTA: 18.50 (+0.88)
Commit To Purchase Prothena Corp At $17.50, Earn 33.1% Annualized Using Options
at The Street - Fri Dec 12, 10:45AM CST
Investors considering a purchase of Prothena Corp plc shares, but tentative about paying the going market price of $17.97/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
PRTA: 18.50 (+0.88)
First patient enrolled in Acorda Phase 3 PD trial
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 7:06AM CST
IPXL: 29.09 (-1.55), ADMS: 14.14 (+0.06), TEVA: 55.15 (-0.47), ACOR: 38.25 (-0.15), PRTA: 18.50 (+0.88), NDRM: 6.34 (-0.47)
Prothena to Present at the Oppenheimer 25th Annual Healthcare Conference in New York
GlobeNewswire - Mon Dec 08, 4:11PM CST
Prothena Corporation plc (Nasdaq
PRTA: 18.50 (+0.88)
Prothena Corporation (PRTA) Falls: Stock Goes Down 5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 7:37AM CST
Shares of Prothena Corporation (PRTA) fell over 5% on the day. This continues the most recent downtrend for PRTA, as the stock is down over 9% since Nov 28. Although this slump was obviously disappointing the company has seen positive revisions and its current year loss consensus has narrowed over the past few weeks.
BIIB: 325.13 (-10.67), ANIP: 55.08 (+1.32), PRTA: 18.50 (+0.88), AFFX: 8.90 (+0.10)
Prothena Initiates NEOD001 Global Phase 3 Registrational Trial Based on Positive Results in Ongoing Phase 1/2 Study of NEOD001 in Patients With AL Amyloidosis
Thomson Reuters ONE - Tue Dec 02, 3:05PM CST
- New and Updated Results Show 50% Response Rate in 14 Cardiac-Evaluable Patients
PRTA: 18.50 (+0.88)
Why You Shouldn't Bet Against Prothena Corporation (PRTA) Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 01, 7:43AM CST
Prothena Corporation might be an intriguing choice for investors as it is seeing solid earnings estimate revision activity and is in great company from a Zacks Industry Rank perspective
PRTA: 18.50 (+0.88)
Prothena's Management Presents at 2014 Credit Suisse Healthcare Conference (Transcript)
SA Transcripts - at Seeking Alpha - Tue Nov 11, 2:16PM CST
PRTA: 18.50 (+0.88)
Prothena Reports Third Quarter 2014 Financial Results and R&D Progress
GlobeNewswire - Mon Nov 03, 5:29PM CST
-- Net cash used in operating activities was $12.3 million in the third quarter, while quarter-end cash position of $306.2 million provides solid runway for advancement of multiple programs
PRTA: 18.50 (+0.88)
Prothena beats by $0.12, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 4:06PM CST
PRTA: 18.50 (+0.88)
Genervon ALS drug shows encouraging results
Seeking Alpha - at Seeking Alpha - Mon Oct 20, 7:27AM CDT
BIIB: 325.13 (-10.67), MNOV: 3.36 (-0.11), CHTP: 6.52 (-0.03), ADMS: 14.14 (+0.06), ACOR: 38.25 (-0.15), BCLI: 3.21 (+0.17), BSX: 12.95 (+0.15), IPXL: 29.09 (-1.55), AVNR: 16.91 (-0.04), ACAD: 30.02 (-0.32), CVTS: (), MRK: 56.80 (-0.15), TEVA: 55.15 (-0.47), PRTA: 18.50 (+0.88), PRAN: 1.84 (-0.04), FOLD: 7.73 (-0.15), CUR: 2.37 (-0.02)
The Next Biotech Buyout Stock
Motley Fool Staff - Motley Fool - Fri Oct 10, 7:15AM CDT
Biotech stocks are notoriously volatile, making them best suited for only the most risk-tolerant investors. But for those willing to take the risk, biotech companies can often make a big splash; particularly when a bigger fish gobbles them up....
JNJ: 102.76 (-1.20), PTLA: 27.37 (unch), PFE: 30.67 (-0.19), BMY: 57.69 (-0.86), PRTA: 18.50 (+0.88), PBYI: 195.44 (+0.11)
Why Prothena Corporation (PRTA) Stock Might be a Great Pick - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 7:43AM CDT
Prothena Corporation belongs to the Medical and Biomedical industry, is a decent pick as it witnessed solid earnings estimate revision activity with a favorable Zacks Industry Rank.
PRTA: 18.50 (+0.88)
Zacks Rank #1 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
KMX: 58.23 (-0.61), CRUS: 22.89 (-0.07), MEI: 32.98 (-0.33), PRTA: 18.50 (+0.88), GPX: 31.25 (-0.02)